SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its Cargocyte™ technology platform at the American Society of Gene and Cell Therapy (ASGCT) annual meeting April 29 – May 2 in Washington, DC.
We are excited to be presenting our preclinical data supporting Cargocytes™, a first-of-its-kind, cell-based platform technology for delivery of an Oncolytic Virus into metastatic tumors,” said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus. “Our technology unleashes the promise of using Oncolytic Viruses to treat solid tumors by addressing a number of critical problems they inherently have, mainly homing the viruses to specific tissue without the immune system destroying it and then delivering those viruses into tumor cells. In addition, we are proud of our growing immune-oncology work with our Cargocytes and look forward to sharing our data at this year’s ASGCT meeting.
Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
Details of the presentations:
Abstract Title: Cargocyte™ Biofactories: A New Versatile Cell Therapy Platform for Delivery of a Wide Range of Biologics
Session Date/Time: Monday Apr 29, 2019 5:00 PM – 6:00 PM
Session title: Cancer-Targeted Gene & Cell Therapy
Room: Columbia Hall
Final abstract number: 272
Abstract Title: Cargocyte™ Biofactories: A Novel Platform for Delivering Oncolytic Viruses to Treat Metastatic Cancer
Session Date/Time: Tuesday Apr 30, 2019 3:30 PM – 5:15 PM
Session title: Oncolytic Viruses II
Room: International Ballroom
Our Presentation Time: 4:00 PM – 4:15 PM
Final abstract number: 404
Abstract Title: Cargocytes™: A Novel Cell Therapy Platform to Drive Anti-Tumor Immunity
Session Date/Time: Tuesday Apr 30, 2019 5:00 PM – 6:00 PM
Session title: Cancer-Immunotherapy, Cancer Vaccines
Room: Columbia Hall
Final abstract number: 578
Cytonus will also be presenting at the Bio International Convention, June 3-6, 2019 in Philadelphia.
Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a biopharmaceutical company developing a next-generation Adoptive Cellular Transport platform called Cargocytes™. The San Diego-based company’s proprietary Cargocyte™ platform are cellular-engineered transporters of a multiplicity of therapeutic payloads to tissue in a selective, controllable and potent off-the-shelf cellular therapy for the potential treatment of several diseases across multiple therapeutic areas. Cytonus’ initial focus is to advance Cargocyte™ candidates for the treatment of rare and difficult to treat cancers and inflammatory diseases. For more information, visit www.cytonus.com or follow us on LinkedIn.
Statements in this news release, which relate to other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.
Original article can be found here.
